Wow.This is certainly different than two weeks ago. As the lady (approximately) said: “Buckle up Folks. It's going to be a bumpy (market).”
Yes it was a good week for the NASDAQ Composite (+5.7%). But we laugh at such paltry gains when compared to the land of biotech, Ha! Ha! (Nasdaq biotech index +7.7%; S&P biotechs gain +8.9%)!!! Wait. Sorry. Somehow I was overcome by the exuberance of animal sprits. I’m calmer now.
But it WAS a good week. Those index gains pushed both biotech composites back into the black YTD. But it’s the particulars for the contest we’re interested in here.
At the top of this week’s performers is CU6.AX, listed (as the “.AX” denotes) on the Australian market. Most of the year it’s been noodling around without drawing much attention to itself. This week, however, since Tuesday morning each day was a signifier gain, with Friday being icing on the cake, to get a a total gain for the week of +59%. There is nothing on the wire, but they are in a promising phase III though the last news was a press release of two months ago.
Second place, is a familiar face: JSPR, +52%, enough to move it up to second place in the YTD standings (+210%). VKTX is still in first YTD (+310%).
In third, VERU returned +50%, and had four articles on the news wire last week. Three of these were from the company: that they will have their quarterly financials announced next week, that they will attend a “summit” meeting, and that they are now enrolling patients for a Phase IIb trial. The third, release Tuesday morning, might be the source of the buy sentiment. (The fourth was a Zacks technical analyst touting the appearance of a “Golden Cross’ as a reason to consider VERU. Private opinion: technical analysis is functionally equivalent to reading tea leaves.)
TMDX (+44%) strongly exceeded expatiations at the release 1st quarter financials, triggering a tsunami of analyst reports. ARDX (+37%) also released Q1 financials AND the announcement of the release of additional performance data at an upcoming meeting.
Looking at the losers, CRDF shows that exceeding expectations in Q1 results on Thursday afternoon was not a guaranteed win. Instead it lost big Friday, for a weeklong loss of -37%. So in this case they clearly disappointed the Market's expectations. But they are still a pretty big win, YTD (+138%), dropping two places in those standings to fourth.
The second worst for the week, KZIA, -22%, with much of the loss after announcing a “Successful Stage I” trial. Not successful enough I guess. BRNS (-8.7%) announced hiring a new Chief Medical office and canceling some elements of the CEO’s compensation. (How often does that happen?) ITRM (-6.1%) announced resubmitting a New Drug Application, with possible approval Q4.
And for the portfolios, this week saw an uptick of $9.7lk in their average value. In fact EVERY portfolio made a profit this week, enough to move five more portfolios into the black YTD.
First place went to BULBAMAN, +$19k, +$11.7k from their faith in CU6.AX. This allowed them to surge past BLADERUNNER by +$9.6k, into first place,YTD (+$76k).
The second best return for the week was DEW_DILIGENCE, $17k, moving them past TECHNETIUM into the fifth place YTD (+$22k).
Report Time Ranges
|
|
|
|
|
| From
| To
|
|
|
|
|
|
|
|
| Recent
| 4/26/24
| 5/3/24
|
|
|
|
|
|
|
|
| YTD
| 12/31/2023
|
|
|
|
| Index Portfolios’ Performance
|
|
|
|
| Symbol
| Recent P/L
| Recent %
| YTD P/L
|
|
|
|
|
|
|
|
| ^IXIC
| $5,824.38
| 5.7%
| $7,627.39
|
|
|
|
|
|
|
|
| ^NBI
| $7,179.11
| 7.7%
| $172.93
|
|
|
|
|
|
|
|
| ^SPSIBI
| $8,246.87
| 8.9%
| $970.29
|
|
|
|
| Share Performance
| Recent Performance
| YTD Performance
|
| Top Five
|
| Bottom Five
|
| Top Five
|
| Bottom 5
| Symbol
| P/L / Initial Price
| Symbol
| P/L / Initial Price
| Symbol
| YTD P/L / Initial Price
| Symbol
| YTD P/L/ Initial Price
| CU6.AX
| 58.7%
| CRDF
| -37.2%
| VKTX
| 313.6%
| AMLX
| -86.2%
| JSPR
| 52.2%
| KZIA
| -22.3%
| JSPR
| 210.8%
| CNSP
| -82.6%
| VERU
| 50.0%
| BRNS
| -8.7%
| PYXS
| 143.3%
| PACB
| -81.3%
| TMDX
| 44.3%
| ITRM
| -6.1%
| CRDF
| 137.8%
| NERV
| -61.5%
| ARDX
| 37.1%
| SCLP.L
| -3.8%
| VERU
| 126.4%
| RVNC
| -55.1%
| Average and Median Portfolio Performance
|
| Recent P/L
|
|
|
| YTD P/L
|
|
|
| Avg.
| Median
|
|
|
| Avg
| Median
|
|
|
| $9,664.37
| $8,832.56
| ARTHUR RADLEY
|
| $12,512.14
| $3,079.50
| KATHLEEN
| Top Seven Portfolio Performances
| Top Recent Performers
| Top YTD Performers
| Contestant (Prev. Rank)
| Recent P/L
| P/L vs. ^SPSIBI
| YTD P/L (Rank)
| Contestant (Prev. Rank)
| YTD P/L
| vs. Top Portfolio
| P/L vs. ^SPSIBI
| Rec. P/L (Rank)
| 1 - BULBAMAN (1)
| $18,938.21
| $10,691.34
| $75,592.86 (1)
| 1 - BULBAMAN (2)
| $75,592.86
| ——
| $74,622.57
| $18,938.21 (1)
| 2 - DEW_DILIGENCE (7)
| $16,937.32
| $8,690.45
| $21,667.94 (5)
| 2 - BLADERUNNER (1)
| $65,966.37
| $9,626.49
| $64,996.09
| $9,195.47 (7)
| 3 - RAJU_BIJLEE (5)
| $14,151.84
| $5,904.97
| $33,238.16 (3)
| 3 - RAJU_BIJLEE (3)
| $33,238.16
| $42,354.71
| $32,267.87
| $14,151.84 (3)
| 4 - KATHLEEN (10)
| $12,088.78
| $3,841.91
| $3,079.50 (9)
| 4 - ERIKOTTO (4)
| $29,708.45
| $45,884.41
| $28,738.16
| $11,722.17 (5)
| 5 - ERIKOTTO (6)
| $11,722.17
| $3,475.31
| $29,708.45 (4)
| 5 - DEW_DILIGENCE (6)
| $21,667.94
| $53,924.93
| $20,697.65
| $16,937.32 (2)
| 6 - DART LANZER (3)
| $9,240.16
| $993.29
| $1,046.62 (11)
| 6 - TECHNETIUM (5)
| $18,735.27
| $56,857.59
| $17,764.98
| $5,848.87 (16)
| 7 - BLADERUNNER (17)
| $9,195.47
| $948.60
| $65,966.37 (2)
| 7 - TRACE I11 (7)
| $10,933.08
| $64,659.78
| $9,962.79
| $6,883.05 (13)
| 8 - JACK HARTMANN (8)
| $8,856.55
| $609.68
| $6,403.99 (8)
| 8 - JACK HARTMANN (8)
| $6,403.99
| $69,188.87
| $5,433.71
| $8,856.55 (8)
| Top Portfolios’ Contents
| Second Place Recent Performance Portfolio (DEW_DILIGENCE)
| Top YTD Performance Portfolio (BULBAMAN)
| Symbol (Rank)
| Initial Allocation
| Value/Total | ROI
| YTD Stock P/L
| Recent Stock P/L
| % Current Price Change for $1,000 P/L
| Symbol (Rank)
| Initial Allocation
| Value/Total | ROI
| YTD Stock P/L
| Recent Stock P/L
| % Current Price Change for $1,000 P/L
| AVIR
| 6.25%
| 6.3% | 22.0%
| $1,382.81
| $483.48
| 13.1%
| CU6.AX
| 20.00%
| 21.2% | 86.5%
| $17,298.05
| $11,749.00
| 2.7%
| BNTX
| 6.25%
| 4.7% | -9.3%
| -$586.66
| $338.07
| 17.6%
| CYTH
| 10.00%
| 5.4% | -5.0%
| -$503.14
| $1,572.33
| 10.5%
| ENTA
| 25.00%
| 31.5% | 52.6%
| $13,191.70
| $7,068.06
| 2.6%
| LRMR
| 10.00%
| 9.7% | 70.7%
| $7,065.93
| $2,912.09
| 5.9%
| FRLN
| 0.00%
| 0.0% | 2.0%
| $408.16
| $0.00
| ----
| PMN
| 10.00%
| 9.7% | 70.4%
| $7,043.48
| -$173.91
| 5.9%
| MRNA
| 6.25%
| 6.7% | 29.4%
| $1,841.90
| $1,105.92
| 12.3%
| SNGX
| 10.00%
| 3.0% | -46.8%
| -$4,677.63
| -$138.16
| 18.8%
| RVNC
| 25.00%
| 10.4% | -49.6%
| -$12,457.01
| $1,760.70
| 7.9%
| TCON
| 10.00%
| 3.0% | -46.9%
| -$4,688.75
| $142.78
| 18.8%
| VIR
| 25.00%
| 21.2% | 2.9%
| $735.86
| $5,371.50
| 3.9%
| TLX.AX
| 15.00%
| 12.5% | 46.8%
| $7,015.70
| $730.09
| 4.5%
| VKTX
| 6.25%
| 19.3% | 273.3%
| $17,151.18
| $809.60
| 4.3%
| VKTX
| 15.00%
| 35.3% | 313.6%
| $47,039.23
| $2,144.01
| 1.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
